Merit Medical Systems, Inc. reported a significant increase in its financial performance for the fiscal year ending December 31, 2025, with total sales reaching $1.516 billion, an increase of $159.4 million or 11.8% compared to $1.357 billion in 2024. The company's net income also rose to $128.5 million, or $2.13 per share, up from $120.4 million, or $2.03 per share, in the previous year. The gross profit margin improved to 48.7%, up from 47.4% in 2024, reflecting favorable pricing and product mix changes, despite higher intangible amortization expenses and manufacturing variances.
The company experienced notable growth in its cardiovascular segment, which accounted for $1.443 billion in sales, a 10.9% increase from the previous year. This growth was driven by a 21.7% increase in cardiac intervention products, bolstered by acquisitions from Cook Medical and Biolife. The endoscopy segment also saw a substantial increase, with sales rising 33% to $72.9 million, primarily due to the acquisition of the EsophyX® Z+ device. International sales contributed significantly, accounting for 40% of total sales, with a 9.1% increase driven by strong performance in the EMEA region.
Strategically, Merit Medical has focused on growth through acquisitions, completing several significant transactions in recent years. In 2025, the company acquired Biolife, a manufacturer of hemostatic devices, for $120 million, and the C2 CryoBalloon® device from Pentax for $19 million. These acquisitions are expected to enhance the company's product offerings and market position. Additionally, Merit has implemented a "Continued Growth Initiatives" program aimed at achieving multi-year financial targets to support sustainable growth and profitability.
Operationally, Merit Medical's workforce has expanded to approximately 7,500 employees across 43 countries, reflecting its commitment to growth and innovation. The company has also made strides in enhancing its research and development capabilities, with a focus on integrating customer feedback into product development. The outlook for 2026 remains positive, with expectations of continued revenue growth driven by new product launches and strategic acquisitions, despite potential challenges from market conditions and regulatory environments.
About MERIT MEDICAL SYSTEMS INC
Merit Medical Systems, Inc. designs, manufactures, and markets proprietary medical devices for interventional, diagnostic, and therapeutic procedures across cardiology, radiology, oncology, critical care, and endoscopy. Its products include catheters, stents, biopsy systems, and procedural kits, serving hospitals and healthcare providers worldwide. The company emphasizes innovation, quality, and customer focus, operating through two segments—cardiovascular and endoscopy—and leveraging global R&D, manufacturing, and distribution to address unmet healthcare needs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.